Zobrazeno 1 - 10
of 193
pro vyhledávání: '"William Pardridge"'
Autor:
Rebecca Lawrence, William Pardridge
Publikováno v:
Drug Discovery Today. 7:223-226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d121fa5e95b596c347ff1d61b023dae
https://doi.org/10.1016/s1359-6446(02)02195-5
https://doi.org/10.1016/s1359-6446(02)02195-5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lawrence, Rebecca N.1 wpardridge@mednet.ucla.edu
Publikováno v:
Drug Discovery Today. Feb2002, Vol. 7 Issue 4, p223. 4p.
Autor:
William Pardridge
Publikováno v:
Trends in Molecular Medicine. 29:343-353
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af3b2a4fb74a371b7e92ed1deaff8682
https://doi.org/10.1016/j.molmed.2023.02.004
https://doi.org/10.1016/j.molmed.2023.02.004
Autor:
William Pardridge
Publikováno v:
Pharmaceutical Research. 40:661-674
Introduction A physiologically based pharmacokinetic (PBPK) model is developed that focuses on the kinetic parameters of drug association and dissociation with albumin, alpha-1 acid glycoprotein (AGP), and brain tissue proteins, as well as drug perme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::479900c9fa9de7acc0a31e7bc881e972
https://doi.org/10.1007/s11095-023-03484-2
https://doi.org/10.1007/s11095-023-03484-2
Autor:
William Pardridge
Publikováno v:
Pharmaceutics. 14(6)
The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914, that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood–brain barrier (BBB). Owing to restricted transport across t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba49efbc1276043c3cade226aa86d316
https://pubmed.ncbi.nlm.nih.gov/35745855
https://pubmed.ncbi.nlm.nih.gov/35745855
Autor:
William Pardridge
Publikováno v:
Pharmaceutics. 15:93
This Special Issue of Pharmaceutics, “Advanced Blood–Brain Barrier Drug Delivery,” comprises 16 articles or reviews, which cover a cross-section of brain drug delivery for either small-molecule or large-molecule therapeutics [...]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f972db6758a8a489ec5b8935f823be4
https://doi.org/10.3390/pharmaceutics15010093
https://doi.org/10.3390/pharmaceutics15010093
Autor:
William Pardridge
Publikováno v:
Advanced Drug Delivery Reviews. 184:114234
The majority of lysosomal storage diseases affect the brain. Treatment of the brain with intravenous enzyme replacement therapy is not successful, because the recombinant lysosomal enzymes do not cross the blood-brain barrier (BBB). Biologic drugs, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eadc60c1313eb464d33962650de9943b
https://doi.org/10.1016/j.addr.2022.114234
https://doi.org/10.1016/j.addr.2022.114234
Autor:
William Pardridge
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 15, Iss 3, p 3 (2022)
Pharmaceuticals, Vol 15, Iss 3, p 3 (2022)
Biologic drugs are large molecule pharmaceuticals that do not cross the blood–brain barrier (BBB), which is formed by the brain capillary endothelium. Biologics can be re-engineered for BBB transport as IgG fusion proteins, where the IgG domain is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159fe9aef8e092f36e7f9c510018f295
https://doi.org/10.3390/ph15010003
https://doi.org/10.3390/ph15010003